Literature DB >> 12415690

Role of receptor tyrosine kinases in lung cancer.

Gautam Maulik1, Takashi Kijima, Ravi Salgia.   

Abstract

Receptor tyrosine kinases are important in normal cellular physiology as well in the pathogenesis of a variety of tumors, including lung cancer. RTKs are a target for novel therapies currently being investigated. In the clinics, EGFR inhibitors and c-Kit inhibitors are already being utilized, and c-Met inhibitors are in development. Even though the RTK inhibitors provide a novel mechanism, it is important to realize that lung cancer etiology is a complex process, and eventually standard chemotherapy may need to be used in conjunction with these novel therapies to make an important difference in response rates.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12415690     DOI: 10.1385/1-59259-323-2:113

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  5 in total

1.  Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2.

Authors:  Mario Acunzo; Giulia Romano; Dario Palmieri; Alessandro Laganá; Michela Garofalo; Veronica Balatti; Alessandra Drusco; Mario Chiariello; Patrick Nana-Sinkam; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-06       Impact factor: 11.205

2.  CD117 immunoreactivity in high-grade neuroendocrine tumors of the lung: a comparative study of 39 large-cell neuroendocrine carcinomas and 27 surgically resected small-cell carcinomas.

Authors:  Giuseppe Pelosi; Michele Masullo; Maria Elena Leon; Giulia Veronesi; Lorenzo Spaggiari; Felice Pasini; Angelica Sonzogni; Antonio Iannucci; Enrica Bresaola; Giuseppe Viale
Journal:  Virchows Arch       Date:  2004-09-16       Impact factor: 4.064

3.  Detection of MET and SOX2 amplification by quantitative real-time PCR in non-small cell lung carcinoma.

Authors:  Yi-Ran Cai; Hai-Qing Zhang; Zong-DE Zhang; Jing Mu; Zi-Hui Li
Journal:  Oncol Lett       Date:  2010-12-23       Impact factor: 2.967

4.  Receptor tyrosine kinases: role in cancer progression.

Authors:  V Sangwan; M Park
Journal:  Curr Oncol       Date:  2006-10       Impact factor: 3.677

5.  Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer.

Authors:  Neelu Puri; Ravi Salgia
Journal:  J Carcinog       Date:  2008
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.